Crossmark

Neostigmine: Mechanism of Action, Dosing, and Factors Determining Adequacy of Recovery Following Administration

Crossref DOI link: https://doi.org/10.1007/s40140-018-0278-1

Published Online: 2018-04-26

Published Print: 2018-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Lorrain, Pierre-Edouard

Schmartz, Denis

Fuchs-Buder, Thomas
License Information

Text and Data Mining valid from 2018-04-26
More Information

Article History

First Online: 26 April 2018

Compliance with Ethical Standards

:

: Pierre-Eduard Lorrain has received compensation from Merck for service as a consultant.Denis Schmartz declares that he has no conflict of interest.Thomas Fuchs-Buder has received compensation from Merck for service as a consultant.

: This article does not contain any studies with human or animal subjects performed by any of the authors.